Kevin Franklin Garris, FNP-C Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 33650 Highway 43, Thomasville, AL 36784 Phone: 334-636-5311 |
Lisa Walker Chaney, FNP-BC Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 33650 Highway 43, Thomasville, AL 36784 Phone: 334-636-5311 Fax: 334-636-2942 |
Jami Beck Mcmanus, CRNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 1415 Mosley Dr, Thomasville, AL 36784 Phone: 334-636-9613 |
Mrs. Jessica K Campbell, CRNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 300 Med Park Dr, Thomasville, AL 36784 Phone: 334-636-2525 Fax: 334-605-3111 |
Yalonda Evette Ferguson, NP Nurse Practitioner - Primary Care Medicare: Accepting Medicare Assignments Practice Location: 33621 Highway 43, Thomasville, AL 36784 Phone: 334-636-5311 |
Brianna Johnson, CRNP Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 1531 N Andrews Dr, Thomasville, AL 36784 Phone: 251-275-6076 |
Donna Palmer, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 321 N Oak Ridge Dr, Thomasville, AL 36784 Phone: 334-830-6047 |
News Archive
The Transportation Security Administration has begun to use whole-body imaging scanners as a primary screening measure on travelers passing through airport security checkpoints. One type of scanner employs millimeter wave technology, which delivers no ionizing radiation.
The National Quality Forum has endorsed outcome measures to assess the results and thereby improve the quality of care provided to people with mental illnesses. The 4 endorsed mental health measures focus on depression and patients' satisfaction during an inpatient psychiatric hospital stay.
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ Chikungunya virus DNA vaccine induced protective neutralizing antibody responses in a preclinical non-human primate model.
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 3 days ago